Description
Anti-FGFR2 Antibody, Non-Fucosylated (BioBet-887ZP) is a humanized monoclonal IgG antibody against FGFR2. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Cancer
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced FGFR2 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Full Name
fibroblast growth factor receptor 2
Background
The protein encoded by this gene is a member of the fibroblast growth factor receptor family, where amino acid sequence is highly conserved between members and throughout evolution. FGFR family members differ from one another in their ligand affinities and tissue distribution. A full-length representative protein consists of an extracellular region, composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. The extracellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. This particular family member is a high-affinity receptor for acidic, basic and/or keratinocyte growth factor, depending on the isoform. Mutations in this gene are associated with Crouzon syndrome, Pfeiffer syndrome, Craniosynostosis, Apert syndrome, Jackson-Weiss syndrome, Beare-Stevenson cutis gyrata syndrome, Saethre-Chotzen syndrome, and syndromic craniosynostosis. Multiple alternatively spliced transcript variants encoding different isoforms have been noted for this gene.
Alternative Names
FGFR2; fibroblast growth factor receptor 2; BEK; JWS; BBDS; CEK3; CFD1; ECT1; KGFR; TK14; TK25; BFR-1; CD332; K-SAM; FGFR-2; FGF receptor; soluble FGFR4 variant 4; bacteria-expressed kinase; hydroxyaryl-protein kinase; FGFR2-AHCYL1 fusion kinase protein; keratinocyte growth factor receptor; BEK fibroblast growth factor receptor; protein tyrosine kinase, receptor like 14
Cellular Localization
Golgi apparatus, Plasma membrane, Extracellular region or secreted
Involvement in Disease
Diseases associated with FGFR2 include Pfeiffer Syndrome and Crouzon Syndrome.
Related Pathways
Its related pathways are RET signaling and Signaling by FGFR2 in disease.
Function
Tyrosine-protein kinase, as the cell surface receptor of fibroblast growth factor, plays an important role in the regulation of cell proliferation, differentiation, migration and apoptosis, and the regulation of embryonic development. It is necessary for normal embryo morphology, trophoblast cell function, limb bud development, lung morphology, osteogenesis and skin development. It plays an important role in regulating the differentiation, proliferation and apoptosis of osteoblasts and is necessary for normal bone development. Promote the proliferation of keratinocytes and immature osteoblasts, but promote the apoptosis of differentiated osteoblasts. Phosphorylate PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of multiple signal cascades. The activation of PLCG1 leads to the production of cell signaling molecules triglycerides and inositol 1,4,5-triphosphate. Phosphorylation of FRS2 triggers the recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates the activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and MAP kinase signaling pathways, and the activation of AKT1 signaling pathways. FGFR2 signaling is down-regulated through ubiquitination, internalization, and degradation. Mutations that cause constitutive kinase activation or impair normal FGFR2 maturation, internalization, and degradation can cause abnormal signaling. Overexpressed FGFR2 promotes the activation of STAT1.
Field of research
Cancer antibody; Cell Biology and Cellular Response antibody; Controls and Markers antibody; Developmental Biology antibody; Neuroscience antibody; Signaling Transduction antibody
Post-translational modifications
Autophosphorylated. Binding of FGF family members together with heparan sulfate proteoglycan or heparin promotes receptor dimerization and autophosphorylation on several tyrosine residues. Autophosphorylation occurs in trans between the two FGFR molecules present in the dimer. Phosphorylation at Tyr-769 is essential for interaction with PLCG1. N-glycosylated in the endoplasmic reticulum. The N-glycan chains undergo further maturation to an Endo H-resistant form in the Golgi apparatus. Ubiquitinated. FGFR2 is rapidly ubiquitinated after autophosphorylation, leading to internalization and degradation. Subject to degradation both in lysosomes and by the proteasome.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Clone
BioBet-887ZP
Description
This is a novel fibroblast growth factor receptor 2 (FGFR2) directed antibody used for cancer therapy. FGFR2 is expressed in a range of tumor types such as gastric, breast, HNSCC, pancreatic and ovarian cancers. FGFR2 has been described to promote tumor growth and survival and play a role in chemotherapy resistance.
Antibody Indication
Cancer
